| Grade 3 Follicular Lymphoma studied in …STUDIED_INderived200 of 214show all (up to 200) |
|---|
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07731789Phase 2 · not yet recruiting Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01318317Phase 1/Phase 2 · active not recruiting Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01849263Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784726Phase 2 · recruiting Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06442475Phase 2 · recruiting Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150329Phase 1 · active not recruiting Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404088Phase 2 · active not recruiting Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07735533Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07750886recruiting Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06471738Phase 2 · recruiting Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714421Phase 1 · not yet recruiting Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05077527Phase 1 · recruiting Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672251Phase 2 · recruiting Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03269669Phase 2 · active not recruiting Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520791Phase 1 · active not recruiting Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205409Phase 2 · completed Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332980Phase 2 · completed Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455697Phase 1/Phase 2 · active not recruiting Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948786Phase 2 · recruiting Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05412290Phase 1 · active not recruiting Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169658Phase 2 · completed Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06014762Phase 1 · active not recruiting P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07545603Phase 2 · recruiting Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859008Phase 1 · recruiting Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476105NA · not yet recruiting Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544265Phase 1 · recruiting SynKIR-310 for Relapsed/Refractory B-NHL · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04450173Phase 2 · active not recruiting Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04088890Phase 1 · completed Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06026319Phase 1 · recruiting CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213913Phase 1/Phase 2 · completed Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446457Phase 2 · active not recruiting Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883437Phase 2 · recruiting Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633615Phase 2 · recruiting Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583149Phase 2 · active not recruiting Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834373Phase 2 · recruiting Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06575686Phase 2 · suspended Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05464329Phase 1 · active not recruiting Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02568553Phase 1 · completed Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01286272Phase 2 · completed Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05890352Phase 2 · recruiting Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02393157Phase 2 · recruiting Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01995669Phase 1/Phase 2 · completed Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02871219Phase 2 · completed Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03583424Phase 1/Phase 2 · completed Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05326243Phase 1/Phase 2 · recruiting Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377307recruiting Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06961500Phase 2 · not yet recruiting Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06093841Phase 2 · active not recruiting Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03410901Phase 1 · completed TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927964Phase 1/Phase 2 · completed TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02532257Phase 2 · completed Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04659044Phase 2 · terminated Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06287398Phase 2 · recruiting Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04995536Phase 1 · withdrawn CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01588015Phase 1 · completed Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769222Phase 1 · terminated Ipilimumab and Local Radiation for Selected Solid Tumors · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01523223Phase 1 · completed Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01193842Phase 1/Phase 2 · completed Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01000753completed Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01044745Phase 2 · terminated Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03010358Phase 1/Phase 2 · completed Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04156828Phase 1 · terminated Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01029366Phase 1 · completed CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05733650approved for marketing Expanded Access Program for Epcoritamab · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00096460Phase 2/Phase 3 · terminated Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04635683Phase 1 · withdrawn Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02049541Phase 1 · completed Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02710643Phase 2 · completed "MIRO" Molecularly Oriented Immuno-radio-therapy · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01261247Phase 2 · completed Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05040555NA · recruiting R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01805037Phase 1/Phase 2 · terminated Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02037256NA · completed Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00536601NA · completed High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01678443Phase 1 · terminated Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00489203Phase 2 · completed Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01258998Phase 2 · completed Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01075321Phase 1/Phase 2 · completed Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02541565Phase 1 · completed Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03097770Phase 1/Phase 2 · completed Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00082888Phase 2 · completed Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00918333Phase 1/Phase 2 · completed Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00040846Phase 2 · completed Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089011Phase 2 · completed Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006251Phase 1/Phase 2 · completed Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00014235NA · completed Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00078858Phase 1/Phase 2 · completed Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01239875early Phase 1 · completed Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003196NA · completed Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01326702Phase 1/Phase 2 · completed Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03487432NA · completed A ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02652715NA · completed Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00856388NA · completed Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00105001Phase 2 · completed Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01529827Phase 2 · completed Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01839916Phase 2 · completed Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02950220Phase 1 · completed Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01159067Phase 2 · terminated Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01408043NA · terminated Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02592876Phase 2 · terminated Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03185494Phase 1/Phase 2 · unknown Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02855359Phase 2 · terminated Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01093586Phase 2 · completed Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02240719Phase 1 · completed Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01719250early Phase 1 · completed Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01273766Phase 2 · completed Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02702141Phase 1 · terminated A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00012298Phase 1/Phase 2 · terminated Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01789255Phase 2 · completed Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01484015Phase 1 · completed Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02168907Phase 1 · terminated CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00119392Phase 2 · completed Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01812005Phase 2 · terminated Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01129193Phase 1 · completed AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02216890Phase 1 · completed Safety Study of SGN-CD70A in Cancer Patients · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01567709Phase 1 · completed Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00253630Phase 2 · completed Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00867529Phase 2 · completed Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01852435Phase 3 · unknown R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B · condition mapped ALIAS · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01682044Phase 2 · completed Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01254578Phase 1 · completed Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00073918Phase 2 · completed Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01419795Phase 2 · terminated Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00072514Phase 2 · completed Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01076270NA · terminated Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00118352Phase 2 · completed Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00601718Phase 1/Phase 2 · completed Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112593NA · completed Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01110135Phase 2 · completed Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00795769Phase 2 · completed Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01427881Phase 2 · completed Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00049504Phase 2 · completed Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02685670Phase 1/Phase 2 · unknown Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00408681NA · completed Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927717unknown An Italian Experience on Grade 3b Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 214 trials mapped (53 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02281279Phase 1/Phase 2 · withdrawn Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112723Phase 1/Phase 2 · terminated Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01652014Phase 2 · withdrawn Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00438880Phase 1/Phase 2 · completed Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01864889NA · unknown Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01748721Phase 1 · completed MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00023764Phase 2 · completed Bortezomib in Treating Patients With Lymphoproliferative Disorders · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00538187Phase 1 · terminated Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01045928Phase 1 · terminated Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01735604Phase 1/Phase 2 · unknown Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02109224Phase 1 · terminated Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01658319Phase 1 · completed Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01959477early Phase 1 · completed Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00608361Phase 1 · completed Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769911NA · withdrawn Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003210Phase 2 · completed Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00343798Phase 1 · completed A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00082784Phase 1 · completed Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01158274Phase 1 · completed RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00275080Phase 1 · completed Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00110071Phase 1 · completed Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01397591Phase 2 · terminated Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00054639Phase 2 · completed Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00058019Phase 2 · completed Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00290472Phase 2 · completed CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01231919Phase 1 · completed MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01233921NA · completed Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00890747Phase 1 · completed Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00096005Phase 1 · terminated Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00499811Phase 1 · completed Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00458731Phase 1 · completed Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00769288Phase 1 · completed FAU in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00019708Phase 1 · terminated Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00293345Phase 1 · completed 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00010192Phase 1 · completed Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00103272Phase 1 · terminated 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00054483Phase 1 · completed Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00354185Phase 1 · terminated PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00348985Phase 1 · completed PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00060372Phase 1 · completed Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00002649Phase 3 · completed Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003204Phase 3 · completed Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00004241Phase 1 · completed 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00025415Phase 1 · completed Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00060112Phase 1 · terminated Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089271Phase 1 · completed 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003970Phase 1 · completed Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00077155Phase 1 · completed Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00086944Phase 1/Phase 2 · completed Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 214 trials mapped (53 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |